Pituitary / ADH Agents
Verified · Oct 2026One hormone, two receptors. V2 saves water; V1 squeezes vessels. Desmopressin keeps the V2 action and drops most of the V1 one; vasopressin keeps both. The V2 antagonists that block this receptor are on the Vasopressin Antagonists page.
Nursing view → administration, monitoring and patient teaching
Compare: The ADH axis compared — diabetes insipidus, SIADH and the drugs that act on V2 →
Drugs
* DDAVP, Stimate (desmopressin): Drugs@FDA lists the Stimate brand as discontinued, although Ferring still has a current Stimate label (2026).
Mechanism
Desmopressin is a synthetic, V2-selective vasopressin analog: it activates renal collecting-duct V2 receptors to insert aquaporin-2 channels, increasing water reabsorption (antidiuresis), and stimulates endothelial release of von Willebrand factor and factor VIII (hemostasis). Native vasopressin also activates V1 receptors on vascular smooth muscle, causing vasoconstriction and raising blood pressure.
V2: how ADH concentrates the urine
In hypovolemia or hypernatremia, ADH is released from the posterior pituitary and binds the V2 receptor on principal cells of the late distal tubule and collecting duct. V2 is Gs-coupled: adenylate cyclase raises cAMP, which activates protein kinase A; the phosphorylation cascade moves aquaporin-2 storage vesicles into the apical membrane. Water then moves passively into the cell down the gradient set by NaCl and urea, and the urine becomes concentrated. When water balance is restored, ADH falls and aquaporin-2 is internalized, leaving the membrane watertight again.
Desmopressin is a selective V2 agonist acting through the same Gs–cAMP cascade, so urine volume falls and urine osmolality rises.
V1: vasoconstriction, and why desmopressin lacks it
Vasopressin also binds V1 receptors on vascular smooth muscle, coupled to Gq/11 → phospholipase C → IP3, which releases intracellular calcium and contracts the muscle; peripheral resistance and blood pressure rise. At pressor doses it also contracts gastrointestinal smooth muscle through V1 receptors, and it releases prolactin and ACTH through V3 receptors.
Changing the structure of arginine vasopressin to desmopressin gave less vasopressor activity and less action on visceral smooth muscle relative to an enhanced antidiuretic activity. Clinically effective antidiuretic doses of desmopressin are therefore usually below the threshold for vascular or visceral smooth-muscle effects.
Central versus nephrogenic DI — the desmopressin test
In central DI ADH secretion fails, so the collecting tubules stay impermeable to water. In nephrogenic DI ADH is secreted normally but a defect in the V2 receptor or its signaling leaves the kidney unresponsive. Either way, large volumes of dilute urine concentrate body fluids, causing hypernatremia, polyuria and polydipsia. Hereditary nephrogenic DI is mostly X-linked (AVPR2 mutations), with a second, aquaporin-2 gene form; in adults, chronic lithium and hypercalcemia predominate. About 20% of patients on chronic lithium develop polyuria: lithium enters principal cells through ENaC and, at cytotoxic concentrations, disrupts aquaporin-2.
A water deprivation test separates them from primary polydipsia: with normal ADH release, dehydration concentrates the urine, whereas in DI the urine stays hypotonic. Desmopressin is then given: urine osmolality rises in central DI (by more than 100% when complete, up to 50% when partial), but only minimally or not at all in nephrogenic DI. The distinction matters because treatment differs — desmopressin replaces ADH in central DI, whereas nephrogenic DI is treated by stopping the offending drug (such as lithium) and with thiazide diuretics; amiloride may also help lithium-induced polyuria (Thiazide Diuretics and Potassium-Sparing Diuretics pages).
Factor VIII and von Willebrand factor
The same cAMP signaling also triggers exocytosis of von Willebrand factor and factor VIII from their storage sites, including endothelial Weibel-Palade bodies. Von Willebrand factor bridges platelet glycoprotein Ib to subendothelial collagen and stabilizes factor VIII. The rise in factor VIII is rapid — evident within 30 minutes — which is why desmopressin is used to prevent or control bleeding in hemophilia A and type 1 von Willebrand disease when factor VIII activity is above 5%.
It is not indicated for severe type 1 disease, it is ineffective in type 3 disease, and in type 2B disease it may cause platelet aggregation, thrombocytopenia and possibly thrombosis. Given more often than every 48 hours, the hemostatic response lessens (tachyphylaxis).
Water intoxication — SIADH by prescription
Because desmopressin keeps the kidney concentrating urine, a patient who keeps drinking retains free water, with physiology similar to the syndrome of inappropriate ADH: dilutional hyponatremia, in which water moves into neurons as extracellular osmolarity falls and the cells swell. Nausea and malaise come first; lower sodium brings headache, obtundation, seizures, coma and respiratory arrest. DDAVP Injection carries a boxed warning for this hyponatremia, which can be severe and life-threatening.
Misdiagnosis is a trap: treating primary polydipsia as DI with desmopressin can cause severe hyponatremia. Desmopressin is cleared largely by the kidney, so its half-life rises in renal impairment, and moderate-to-severe renal impairment contraindicates it. (Drugs that do the opposite — V2 antagonists that cause an aquaresis — are on the Vasopressin Antagonists page.)
Vasopressin as a pressor
In vasodilatory shock that stays hypotensive despite fluids and catecholamines, therapeutic doses of vasopressin constrict most vascular beds — splanchnic, renal and cutaneous — raising systemic vascular resistance and mean arterial pressure and lowering the norepinephrine requirement; heart rate and cardiac output tend to fall. The pressor effect peaks within 15 minutes and fades within 20 minutes of stopping, with no evidence of tachyphylaxis. The price of V1 vasoconstriction is ischemia — myocardial, mesenteric and distal limb. (Vasopressin among the other shock pressors: Vasopressors page.)
Comparing the drugs
Receptors, actions and uses
| Drug | V2 (collecting duct) | V1 (vascular smooth muscle) | Hemostatic effect | Main uses |
|---|---|---|---|---|
| Desmopressin | Selective agonist → antidiuresis | Little vasopressor activity at antidiuretic doses | Releases von Willebrand factor and factor VIII | Central DI; primary nocturnal enuresis (tablets); hemophilia A and type 1 von Willebrand disease with factor VIII above 5%; distinguishing central from nephrogenic DI |
| Vasopressin | Agonist → antidiuresis | Agonist → vasoconstriction (Gq → calcium) | — | Vasodilatory shock despite fluids and catecholamines |
— = not a use of the drug on these labels.
Polyuria: telling the causes apart
| Drug | ADH problem | Urine after water deprivation | Urine after desmopressin | Treatment |
|---|---|---|---|---|
| Central DI | ADH secretion fails | Stays dilute | Osmolality rises (> 100% if complete, up to 50% if partial) | Desmopressin |
| Nephrogenic DI | Kidney unresponsive (V2 receptor or signaling defect; lithium, hypercalcemia) | Stays dilute | Little or no rise | Stop the cause (e.g. lithium); thiazide diuretic |
| Primary polydipsia | None — thirst is dysregulated | Concentrates | Not needed | Not desmopressin (risk of severe hyponatremia) |
Pharmacokinetics
- Route changes exposure — desmopressin
- Oral DDAVP has about 5% of the bioavailability of the intranasal form and about 0.16% of the intravenous form, so the routes are not interchangeable dose for dose. Plasma half-life after oral or intranasal dosing is about 1.5–2.5 hours (3.3–3.5 hours with the intranasal hemostatic spray).
- Kidney clearance — desmopressin
- Desmopressin is not metabolized by CYP450 and is mainly excreted in the urine. After a single IV dose the terminal half-life was 2.8 hours with normal renal function and 8.7 hours with severe renal impairment, where AUC was 3.6-fold higher — the basis for contraindicating it when creatinine clearance is below 50 mL/min.
- Vasopressin: minutes, not hours — vasopressin
- At shock infusion rates the apparent half-life is 10 minutes or less. Proteases cleave it to inactive fragments and only about 6% is excreted unchanged. Placental vasopressinase raises its clearance about 4-fold by the third trimester. Indomethacin prolongs its effect on cardiac index and vascular resistance.
Uses & drug choice
- Central (ADH-deficient) diabetes insipidus — desmopressin
- Primary nocturnal enuresis — desmopressin tablets (the nasal spray is not indicated for enuresis)
- Bleeding in mild-to-moderate type 1 von Willebrand disease and hemophilia A when factor VIII levels are above 5%, and uremic platelet dysfunction — desmopressin (not severe type 1 disease, and not type 2B, where it may cause thrombocytopenia and possibly thrombosis)
- Vasodilatory (e.g., septic) shock that stays hypotensive despite fluids and catecholamines — vasopressin (V1 vasopressor); also used off-label for variceal bleeding
Adverse effects
- Hyponatremia, seizures, coma (desmopressin)
- V2 agonism keeps aquaporin-2 in the membrane, so free water is retained as long as intake continues — a picture like SIADH. As extracellular osmolarity falls, water moves into neurons, and neuronal swelling causes headache, seizures, coma and respiratory arrest. Drugs that also cause hyponatremia, older age, childhood and reduced kidney function add to the risk.
- Thrombocytopenia in type 2B von Willebrand disease
- Desmopressin releases von Willebrand factor; in type 2B disease this may cause platelet aggregation, thrombocytopenia and possibly thrombosis, so type 2B is a labeled contraindication.
- Myocardial, mesenteric and limb ischemia (vasopressin)
- V1-mediated vasoconstriction in most vascular beds — splanchnic, renal and cutaneous — raises blood pressure but can compromise organ perfusion.
- Diabetes insipidus after vasopressin is stopped
- With the infusion — and its V2 antidiuresis — withdrawn, some patients develop polyuria, dilute urine and hypernatremia; urine output, fluid status and electrolytes are monitored, and some need vasopressin again or desmopressin.
Toxicity & antidote
There is no antidote to desmopressin. The main danger of overdose is water intoxication, which can cause a delayed loss of consciousness and seizures; patients need intensive care monitoring and electrolyte correction. If hyponatremia occurs, desmopressin may need to be stopped temporarily or permanently, and fluid intake is restricted.
Contraindications
- Hyponatremia or a history of it (all desmopressin labels); known or suspected SIADH (injection and Stimate labels) — Adding water retention to an already low or over-diluted sodium risks severe, symptomatic hyponatremia.
- Moderate-to-severe renal impairment (creatinine clearance < 50 mL/min) — desmopressin — Impaired free-water excretion greatly increases the risk of water intoxication.
- Desmopressin injection — heart failure, uncontrolled hypertension, polydipsia, illnesses that can cause fluid or electrolyte imbalance (e.g., gastroenteritis, salt-wasting nephropathy, systemic infection), or use of loop diuretics or systemic/inhaled glucocorticoids — Labeled contraindications for DDAVP Injection: fluid retention can worsen heart failure and hypertension, and polydipsia or these drugs raise the risk of severe hyponatremia.
- Other desmopressin forms — conditions with fluid overload (e.g., heart failure) or polydipsia use caution — These patients cannot handle the added water load and are prone to dilutional hyponatremia — use with caution and close sodium monitoring.
- Desmopressin in very young children (especially under 2 years) use caution — Their water and fluid intake is hard to restrict, so StatPearls advises avoiding desmopressin in younger patients, especially under age 2; the Stimate label says not to use it in infants younger than 11 months for hemophilia A or von Willebrand disease.
- Vasopressin — heart disease or peripheral vascular disease (patients vulnerable to ischemia or with poor cardiac function) use caution — V1 vasoconstriction can cause myocardial, mesenteric, or limb ischemia and can lower cardiac index.
- Desmopressin (Stimate) — type 2B von Willebrand disease — A labeled contraindication: in type 2B disease desmopressin can cause platelet aggregation, thrombocytopenia, and possibly thrombosis.
High-yield
- V1: Gq → calcium → vascular smooth muscle contracts (vasopressin as a pressor)
- V2: Gs → cAMP → aquaporin-2 → water saved (desmopressin, central DI)
Desmopressin is V2-selective — antidiuresis with little pressor effect.
Practice questions
Q1A 38-year-old man develops polyuria of 6 L/day after transsphenoidal pituitary surgery. Serum sodium is 147 mEq/L and urine osmolality stays low during water deprivation. After a dose of desmopressin, urine osmolality more than doubles.
Which signaling event explains his response to desmopressin?
- A.Gq activation and IP3-mediated calcium release in vascular smooth muscle
- B.Inhibition of the Na⁺–Cl⁻ cotransporter in the distal tubule
- C.Blockade of the V2 receptor, producing aquaresis
- D.Opening of ENaC in collecting-duct principal cells
- E.Gs activation, a rise in cAMP and insertion of aquaporin-2 into the apical membrane
Show answer
E. Gs activation, a rise in cAMP and insertion of aquaporin-2 into the apical membrane — He has central DI: water deprivation failed to concentrate the urine, and desmopressin, a selective V2 agonist, raised urine osmolality. V2 is Gs-coupled; cAMP activates protein kinase A, which inserts aquaporin-2 into the apical membrane. Gq–IP3 signaling is the V1 vascular pathway, and V2 blockade is the action of the vasopressin antagonists. Thiazides act on the Na⁺–Cl⁻ cotransporter, and ENaC is a sodium channel — the route by which lithium enters principal cells — whereas water crosses through aquaporin-2.
Q2A 52-year-old woman with bipolar disorder on lithium for 15 years has polyuria and thirst. Urine osmolality stays low during water deprivation and does not rise after desmopressin.
What is the most likely mechanism of her polyuria?
- A.Lithium entering principal cells through ENaC and disrupting aquaporin-2
- B.Failure of ADH secretion from the posterior pituitary
- C.Excess ADH causing dilutional hyponatremia
- D.Primary polydipsia suppressing ADH release
Show answer
A. Lithium entering principal cells through ENaC and disrupting aquaporin-2 — No response to desmopressin means nephrogenic DI. About 20% of patients on chronic lithium develop it: lithium enters collecting-duct principal cells through ENaC and disrupts aquaporin-2. Failure of ADH secretion is central DI, which would respond to desmopressin, and excess ADH (SIADH) causes water retention, not polyuria. In primary polydipsia the urine concentrates during water deprivation, which hers did not.
Q3A 24-year-old woman with type 1 von Willebrand disease (factor VIII activity 30%) is to have a dental extraction. She is given desmopressin.
How does desmopressin reduce her bleeding risk?
- A.It inhibits plasmin-mediated fibrinolysis
- B.It replaces factor VIII directly
- C.It triggers exocytosis of von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies
- D.It activates V1 receptors, constricting the bleeding vessels
Show answer
C. It triggers exocytosis of von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies — The cAMP signaling that desmopressin triggers also releases stored von Willebrand factor and factor VIII, including from Weibel-Palade bodies; factor VIII rises within 30 minutes. It is a synthetic vasopressin analog, not a factor concentrate, and it has little V1 vasopressor activity. Rather than inhibiting fibrinolysis, desmopressin raises plasminogen activator along with factor VIII. In type 2B disease the same release can cause thrombocytopenia.
Q4A 74-year-old man starts desmopressin for nocturia. He keeps his usual evening fluid intake. Ten days later he is confused and has a seizure; serum sodium is 118 mEq/L.
Which process best explains his neurologic findings?
- A.Osmotic demyelination from too-rapid sodium correction
- B.V1-mediated cerebral vasoconstriction
- C.Hypernatremic dehydration of neurons
- D.Water retention lowering extracellular osmolarity, so water enters and swells neurons
Show answer
D. Water retention lowering extracellular osmolarity, so water enters and swells neurons — Desmopressin keeps the kidney retaining water while he continues to drink — an SIADH-like state — so serum sodium falls; as extracellular osmolarity drops, water moves into neurons and the swelling causes confusion, seizures and coma. Older age raises the risk. Desmopressin has little V1 vasopressor activity, hypernatremia is the picture of untreated DI, and osmotic demyelination is a complication of correcting hyponatremia too fast, not of the hyponatremia itself.
Q5A 66-year-old woman in septic shock remains hypotensive despite fluids and norepinephrine, and vasopressin is added. Her pressure improves. Two days later the vasopressin is stopped, and over the next hours her urine output rises sharply and serum sodium climbs to 150 mEq/L.
What is the most likely explanation?
- A.SIADH caused by sepsis
- B.Reversible diabetes insipidus after vasopressin withdrawal
- C.Rebound vasoconstriction from V1 receptor upregulation
- D.Primary polydipsia
Show answer
B. Reversible diabetes insipidus after vasopressin withdrawal — The vasopressin label warns of reversible diabetes insipidus — polyuria, dilute urine and hypernatremia — after the infusion is stopped; urine output, fluid status and electrolytes are monitored, and some patients need vasopressin again or desmopressin. SIADH would retain water and lower sodium. After the infusion is stopped, vasopressin’s pressor effect simply fades within 20 minutes, and vasoconstriction would not explain a dilute polyuria with a rising sodium. Primary polydipsia gives a normal or low plasma osmolality, not a rising sodium.
Sources
- Desmopressin — V2 mechanism, DI/enuresis/hemostasis uses, hyponatremia/water intoxication risk — StatPearls (NCBI)
- Physiology, Vasopressin — ADH water regulation and V1 vasoconstriction — StatPearls (NCBI)
- DDAVP Injection (desmopressin) — boxed warning: hyponatremia; contraindications (FDA label) — DailyMed (NLM)
- DDAVP Tablets (desmopressin) — central DI, primary nocturnal enuresis (FDA label) — DailyMed (NLM)
- STIMATE (desmopressin nasal spray) — hemophilia A / von Willebrand disease (FDA label) — DailyMed (NLM)
- Desmopressin acetate nasal spray — central DI (FDA label) — DailyMed (NLM)
- VASOSTRICT (vasopressin) — vasodilatory shock (FDA label) — DailyMed (NLM)
- Drugs@FDA marketing status — DDAVP, Stimate, Nocdurna, Vasostrict — U.S. FDA (openFDA)
- The use of stems in the selection of INN — -pressin — World Health Organization
- Hyponatremia — hypertonic saline for severe symptoms — StatPearls (NCBI)
- Electrolytes — serum sodium reference range — StatPearls (NCBI)
- Sengstaken-Blakemore Tube — pharmacologic agents for variceal hemorrhage — StatPearls (NCBI)
- Arginine vasopressin vs noradrenaline in experimental septic shock — vasopressin cautioned in heart and peripheral vascular disease (Crit Care, CC BY) — Critical Care (BMC) via PMC
- Arginine Vasopressin Disorder (Diabetes Insipidus) — causes, lithium, desmopressin response, treatment — StatPearls (NCBI)
- Amiloride — lithium-induced polyuria — StatPearls (NCBI)
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.